Integral Health Asset Management LLC Decreases Stake in Eli Lilly and Company (NYSE:LLY)

Integral Health Asset Management LLC lowered its position in Eli Lilly and Company (NYSE:LLY) by 16.7% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 10,000 shares of the company’s stock after selling 2,000 shares during the period. Integral Health Asset Management LLC’s holdings in Eli Lilly and Company were worth $9,054,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Swedbank AB purchased a new position in Eli Lilly and Company in the 1st quarter valued at $932,797,000. Vanguard Group Inc. lifted its holdings in Eli Lilly and Company by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock valued at $56,592,709,000 after purchasing an additional 1,133,810 shares in the last quarter. Wulff Hansen & CO. raised its holdings in shares of Eli Lilly and Company by 90,438.0% during the 2nd quarter. Wulff Hansen & CO. now owns 937,068 shares of the company’s stock worth $848,403,000 after acquiring an additional 936,033 shares during the period. GQG Partners LLC raised its holdings in shares of Eli Lilly and Company by 20.2% during the 1st quarter. GQG Partners LLC now owns 3,848,886 shares of the company’s stock worth $2,994,280,000 after acquiring an additional 648,094 shares during the period. Finally, Capital International Investors raised its holdings in shares of Eli Lilly and Company by 8.1% during the 4th quarter. Capital International Investors now owns 6,636,833 shares of the company’s stock worth $3,868,559,000 after acquiring an additional 497,079 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $921.49 on Monday. The stock has a 50-day simple moving average of $895.06 and a 200-day simple moving average of $838.73. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The stock has a market capitalization of $875.79 billion, a PE ratio of 135.71, a PEG ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 1 year low of $516.57 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 58,749 shares of Eli Lilly and Company stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $915.26, for a total value of $53,770,609.74. Following the completion of the transaction, the insider now owns 97,308,620 shares in the company, valued at approximately $89,062,687,541.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders sold 425,000 shares of company stock worth $394,455,351. 0.13% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

LLY has been the topic of several analyst reports. Bank of America lifted their price target on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Berenberg Bank lifted their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Citigroup initiated coverage on Eli Lilly and Company in a report on Friday, September 13th. They set a “buy” rating and a $1,060.00 price target on the stock. Finally, BMO Capital Markets lifted their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $977.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.